1.06
+1.92%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Allogene Therapeutics
From its filings with the US Securities and Exchange Commission
Allogene Therapeutics is based in South San Francisco, California. Its shares trade on Nasdaq under the ticker ALLO. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $190.9m. At that date it held total assets of $415.9m and shareholders' equity of $292.5m.
We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. We are developing a pipeline of “off-the-shelf” T cell product candidates that are designed to target and kill cancer cells in patients or eliminate pathogenic autoreactive cells in patients with autoimmune disorders. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient’s use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients.
After nearly eight years of platform development and treatment of more than 200 patients across six clinical studies, multiple anticipated clinical readouts are expected in the second quarter of 2026. These readouts could begin to validate several key scientific and clinical assumptions underlying off-the-shelf CAR T therapy, including biologic activity, safety, and the feasibility of standardized, readily available cell therapy across oncology and autoimmune indications.
Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 11 Oct 2018
- Employees
- 150
- Website
- allogene.com ↗
- Head office
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Arie BelldegrunExecutive Chairman of the Board, since 2017$3.0m
- Dr. David ChangPresident, Chief Executive Officer, Co-Founder, Director, since 2018$4.5m
- Mr. Geoffrey ParkerChief Financial Officer, Executive Vice President
- Dr. Zachary RobertsExecutive Vice President - Research and Development, Chief Medical Officer$2.2m
- Mr. Benjamin BeneskiSenior Vice President, Chief Technical Officer
- Mr. Earl DouglasSenior Vice President, General Counsel, Compliance Officer and Corporate Secretary
- Mr. Joshua KazamDirector, since 2017$352,650
- Ms. Elizabeth BarrettIndependent Director$353,540
- Mr. John DeYoungIndependent Director
- Dr. Franz HumerIndependent Director$421,714
- Dr. Stephen MayoIndependent Director$346,150
- Ms. Deborah MessemerIndependent Director$369,998
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 59
- Environment
- 53
- Social
- 99
- Governance
- 24
- Women in the workforce
- 52%
- Carbon reduction policy
- No
- Human rights policy
- Yes
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.